You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed and Refractory Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed/Refractory Lymphoma Trial in Shanghai (tazemetostat, HMPL-689)

Not yet recruiting
  • Relapsed/Refractory Lymphoma
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Feb 2, 2023

Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Lymphoma
  • CD70-targeting CAR-T cells
  • Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 9, 2023

Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed Trial in United States (MT-601)

Recruiting
  • Non-Hodgkin Lymphoma, Adult
  • +3 more
  • Duarte, California
  • +3 more
Apr 4, 2023

Lymphoma Trial (6MW3211)

Not yet recruiting
  • Lymphoma
  • (no location specified)
Jul 2, 2022

Relapsed/Refractory Lymphoma Trial in Chengdu (TQB2618 injection, Penpulimab injection)

Recruiting
  • Relapsed/Refractory Lymphoma
  • TQB2618 injection
  • Penpulimab injection
  • Chengdu, Sichuan, China
    Sichuan Cancer Hospital
Jun 1, 2022

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

Active, not recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • BEBT-908 for injection
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023

Advanced Solid Tumor, Lymphoma, NSCLC Trial in Chaoyang, Cangzhou, Tianjin (BPI-371153)

Not yet recruiting
  • Advanced Solid Tumor
  • +3 more
  • Chaoyang, Beijing, China
  • +3 more
Jun 15, 2022

Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)

Recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • infusion of JY231 injection
  • Guangzhou, Guangdong, China
    Guangdong Second Provincial General Hospital
Sep 17, 2023

Relapsed or Refractory B-cell Lymphoma Trial (Relmacabtagene Autoleucel Injection)

Not yet recruiting
  • Relapsed or Refractory B-cell Lymphoma
  • Relmacabtagene Autoleucel Injection
  • (no location specified)
Apr 13, 2023

Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Relapsed/Refractory B-Cell Lymphoma
  • (no location specified)
Jul 10, 2023

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)

Recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Beijing, Beijing, China
    Han wei dong
Jun 14, 2023

SALVAGE TREATMENT WITH GLOFITAMAB IN RELAPSED/REFRACTORY B-NHL:

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • +2 more
    • (no location specified)
    Jun 22, 2023

    Relapsed/Refractory Lymphoma Trial in Shanghai (F527)

    Not yet recruiting
    • Relapsed/Refractory Lymphoma
    • Shanghai, Shanghai, China
      Ruijin Hospital Affiliated to Shanghai Jiaotong University Schoo
    Mar 14, 2022

    Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

    Not yet recruiting
    • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
    • (no location specified)
    Jun 28, 2023

    Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

    Recruiting
    • Peripheral T Cell Lymphoma
    • +2 more
    • Chidamide combined with Duvillisib
    • Xiamen, Fujian, China
      The First Affiliated Hosptial of Xiamen University
    Nov 28, 2023

    Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)

    Not yet recruiting
    • Relapsed/Refractory Large B-cell Lymphoma
    • (no location specified)
    Oct 6, 2023

    Relapsed/Refractory Lymphoma Trial in Beijing (Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection)

    Recruiting
    • Relapsed/Refractory Lymphoma
    • Recombinant humanized anti-CD47/PD-1 bifunctional antibody HX009 injection
    • Beijing, Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciense
    Jan 10, 2022

    Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

    Recruiting
    • Diffuse Large B-cell Lymphoma Recurrent
    • Diffuse Large B Cell Lymphoma Refractory
    • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Oct 12, 2023

    Mantle-cell Lymphoma Trial (Polatuzumab, bendamustin und rituximab)

    Not yet recruiting
    • Mantle-cell Lymphoma
    • Polatuzumab, bendamustin und rituximab
    • (no location specified)
    May 11, 2023

    Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

    Recruiting
    • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
    • thiotepa combined with pomalidomide
    • Nanjing, Jiangsu, China
      Jiangsu Province People's Hospital.
    Jun 27, 2023

    Lymphoma, Primary Effusion Trial run by the National Cancer Institute (NCI) (Daratumumab SC)

    Not yet recruiting
    • Lymphoma, Primary Effusion
    • Daratumumab SC
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jun 23, 2023

    Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)

    Not yet recruiting
    • Relapsed/Refractory Non-Hodgkin Lymphoma
    • Duarte, California
    • +1 more
    Oct 13, 2023

    Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

    Not yet recruiting
    • Relapsed or Refractory B-cell Lymphoma
    • Shanghai, Shanhai, China
      Ruijin Hospital
    Sep 29, 2023